Skip to main content

Below, you can find answers to commonly asked questions about the CeQur Simplicity™ wearable insulin patch. If you need further assistance, you can get in touch with our CeQur Care team or your healthcare provider.

About CeQur Simplicity

Getting Started

Features and Benefits

Safety and Care

The Inserter is reusable. Do not throw it away. You can clean the Inserter by wiping it with soapy water, then rinsing with clean water and allowing it to air dry.

The wearable insulin patch does not track insulin doses at this time.

To make the screening process go smoothly, you should review the airline’s security requirements and carry a copy of a letter from your healthcare provider stating your need to carry insulin supplies.

Please contact CeQur Care at 1-888-55-CeQur (1-888-552-3787) or for assistance.

The introducer needle (red cap) and fill syringe needle should be placed in a sharps container and disposed of according to local regulations. The CeQur Simplicity patch itself contains no sharps and should be thrown away according to local environmental regulations for medical waste.

The patches should be stored in a cool, dry place from 50 to 77°F (10 to 25°C). Extreme heat or cold can cause patches to malfunction.

Contacting CeQur Care

Our CeQur Care team is available between 9 a.m. and 6 p.m. ET, Monday through Friday,
at 1-888-55-CeQur (1-888-552-3787) or

We’re here to help you join the injection-free revolution. Give us a call if you need assistance with CeQur Simplicity. If you’re experiencing a medical emergency, call 911 or go to your nearest emergency room.

  1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
  2. Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal R. 2018. Comparing Patch vs. Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Diabetes 2018 Jul; 67(Supplement 1).
  3. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.
  4. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. 2018. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. Diabetes Therapy. 9(1):297–307.
  5. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.
  6. Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T, Bosi E, Buckingham B, Cefalu W, Close K, Cobelli C, Dassau E, DeVries J, Donaghue K, Dovc K, Doyle F, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch I, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy H, Nimri R, Nørgaard K, Parkin C, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer S, Phillip M. 2019. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care Aug 2019, 42 (8) 1593-1603.
  7. Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molich M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle R, Dreon D, Tan M. 2011. Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study. Diabetes Technology & Therapeutics. 13(10):1031-1037.
  8. 2020 HEDIS Measures summary of changes. HEDIS Measures and Technical Resources 2020  [cited 2020 March 9]; available from:
  9. Peyrot M, et al. Correlates of insulin injection omission. Diabetes Care. 2010; 33(2): p. 242-243 charts, discussion p. 244.
  10. Barry R, Johns DON, Rees B. 2329-PUB: Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement. Diabetes, 2019. 68(Supplement 1): p. 2329-PUB. This is a post-hoc analysis done on Bergenstal Trial.

  11. Results from standardized dQ&A patient survey. Data on file at CeQur.